Brief: Edgewise Therapeutics Announces Expansion Of Edg-5506 Clinical Program In Duchenne Muscular Dystrophy

Edgewise Therapeutics

26/10/2023 13:30

Oct 26 (Reuters) - Edgewise Therapeutics Inc  EWTX.O :
    * EDGEWISE THERAPEUTICS ANNOUNCES EXPANSION OF THEIR
EDG-5506
CLINICAL PROGRAM IN DUCHENNE MUSCULAR DYSTROPHY (DUCHENNE)
    * EDGEWISE THERAPEUTICS INC - INITIATING NEW PHASE 2 FOX
TRIAL IN
BOYS WITH DUCHENNE WHO HAVE BEEN PREVIOUSLY TREATED WITH GENE
THERAPY
    * EDGEWISE THERAPEUTICS - CONTINUING DOSE ESCALATION OF
PHASE 2
LYNX TRIAL & INITIATING COHORT IN BOYS WITH DUCHENNE NOT TREATED
WITH CORTICOSTEROIDS
    * EDGEWISE THERAPEUTICS INC - COMPANY EXPECTS TO REPORT
PHASE 2
INTERIM DATA IN FIRST HALF OF 2024, WITH PHASE 3 DOSE IDENTIFIED

Source text for Eikon:  ID:nBw5hsyna 
Further company coverage:  EWTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))